Panbela Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 7.83 million compared to USD 4.4 million a year ago. Basic loss per share from continuing operations was USD 53.8.
For the nine months, net loss was USD 18.79 million compared to USD 30.2 million a year ago. Basic loss per share from continuing operations was USD 287.